{
  "id": 11681196,
  "title": "Psilocybin shows early promise for lingering Lyme disease symptoms",
  "url": "https://urgent.news/2026/10/03/psilocybin-shows-early-promise-for-lingering-lyme-disease-symptoms",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-03T12:00:50.000Z",
  "source": {
    "name": "PsyPost",
    "slug": "psypost",
    "url": "https://www.psypost.org/psilocybin-shows-early-promise-for-lingering-lyme-disease-symptoms/"
  },
  "original_language": "en",
  "account": "A small pilot study of 20 individuals with post-treatment Lyme disease (PTLD) found that, 6 months after two psilocybin sessions accompanied by psychological support, their overall symptom burden was 40% lower than at the beginning of the study. Health-related quality of life had also improved significantly. The study, published in Scientific Reports, aimed to explore the potential benefits of psilocybin in alleviating PTLD symptoms, which can persist for months or years after standard antibiotic treatment. PTLD symptoms, including fatigue, pain, sleep problems, and cognitive difficulties, can significantly impact daily functioning and quality of life. While the exact cause of PTLD is not fully understood, it is believed to stem from lingering immune changes, tissue injury from the initial infection, or other biological or psychological factors. The study authors, led by Albert Garcia-Romeu from the Johns Hopkins University School of Medicine, hypothesized that classic psychedelics like psilocybin could help improve symptoms and quality of life in patients with chronic illnesses that have not responded to conventional treatments. Psilocybin, LSD, DMT, and mescaline are examples of classic psychedelics that primarily affect perception, mood, and cognition through serotonin receptor activity. Although illegal or tightly controlled in many countries, researchers are investigating their potential in treating mental health conditions, with positive results reported in clinical trials. The study included 20 patients with PTLD, recruited primarily from previous Johns Hopkins Lyme Disease Research Center studies and through online advertisements. Participants, with an average age of 44, had a median illness duration of 5.7 years and were predominantly white (90%). After completing an 8-week intervention that involved two psilocybin sessions and psychological support, participants' overall symptom burden was 42% lower at 1 month post-treatment, and this reduction remained steady through the 6-month follow-up. Mental and physical quality of life scores also improved by approximately 13% at 6 months. Mood, fatigue, sleep quality, and pain all showed significant improvements, with depressive symptoms being roughly 50% to 60% lower than at the study's start. No serious adverse events were reported, and all participants completed both dosing sessions.",
  "summary": "Up to one in five Lyme patients keep experiencing symptoms after antibiotics. A new pilot study suggests psilocybin-assisted therapy might help, with symptom burden 40% lower six months later, though larger controlled trials are needed.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}